We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.02%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$201M
AUM Growth
+$31.2M
Cap. Flow
+$76.3K
Cap. Flow %
0.04%
Top 10 Hldgs %
56.18%
Holding
53
New
12
Increased
15
Reduced
7
Closed
9
Avg Time Held
3.5 quarters
Top 10 Avg Time Held
1.8 quarters
Top 20 Avg Time Held
2.7 quarters

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$7.46M
2
IMMU
Immunomedics Inc
IMMU
+$4.86M
3
OCUL icon
Ocular Therapeutix
OCUL
+$3.8M
4
VIRX icon
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.25M
5
CTMX icon
CytomX Therapeutics
CTMX
+$2.24M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$12.4M
2
NGNE icon
Neurogene
NGNE
+$3.95M
3
MGNX icon
MacroGenics
MGNX
+$3.48M
4
OMER icon
Omeros
OMER
+$2.63M
5
CLSD icon
Clearside Biomedical
CLSD
+$2.41M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
2 Miscellaneous 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZSAN
26
DELISTED
Zosano Pharma Corporation
ZSAN
$2.38M 1.18%
+1,786
New +$2.16M
2017 Q1
0 quarters
VIRX icon
27
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.25M 1.12%
+15,714
New +$2.25M
2017 Q1
0 quarters
WVE icon
28
Wave Life Sciences
WVE
$603M
$2.15M 1.07%
+78,300
New +$2.19M
2017 Q1
0 quarters
GNMX icon
29
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.99M 0.99%
1,070,000
-430,000
-29% -$1.95M
2014 Q4
9 quarters
PTLA
30
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.96M 0.98%
+50,000
New +$1.59M
2017 Q1
0 quarters
IOVA icon
31
Iovance Biotherapeutics
IOVA
$6.49B
$1.71M 0.85%
230,000
-70,000
-23% -$513K
2016 Q2
3 quarters
XENE icon
32
Xenon Pharmaceuticals
XENE
$3.26B
$1.44M 0.72%
360,000
-45,000
-11% -$354K
2015 Q3
6 quarters
NGNE icon
33
Neurogene
NGNE
$435M
$1.42M 0.71%
4,250
-11,250
-73% -$3.95M
2016 Q2
3 quarters
ABEO icon
34
Abeona Therapeutics
ABEO
$246M
$1.38M 0.68%
11,000
-5,000
-31% -$645K
2016 Q3
2 quarters
TNXP icon
35
Tonix Pharmaceuticals
TNXP
$110M
– –
0
– –
2017 Q1
0 quarters
CDTX icon
36
DELISTED
Cidara Therapeutics
CDTX
$955K 0.48%
+6,125
New +$1.08M
2017 Q1
0 quarters
ALBO
37
DELISTED
Albireo Pharma Inc
ALBO
$876K 0.44%
+36,500
New +$794K
2017 Q1
0 quarters
KPTI icon
38
Karyopharm Therapeutics
KPTI
$7.89M
$770K 0.38%
+4,000
New +$642K
2017 Q1
0 quarters
CORI
39
DELISTED
Corium International, Inc.
CORI
$677K 0.34%
162,000
-218,000
-57% -$800K
2015 Q4
5 quarters
ARQL
40
DELISTED
Arqule Inc
ARQL
$593K 0.3%
+560,000
New +$747K
2017 Q1
0 quarters
SYRS icon
41
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$400K 0.2%
+2,515
New +$307K
2017 Q1
0 quarters
XOMA icon
42
DELISTED
Xoma
XOMA
$287K 0.14%
+40,400
New +$208K
2017 Q1
0 quarters
BLRX icon
43
BioLineRX
BLRX
$10.7M
$240K 0.12%
417
– –
2013 Q4
13 quarters
CLSD icon
44
DELISTED
Clearside Biomedical
CLSD
– –
-18,000
Closed -$2.41M –
MGNX icon
45
MacroGenics
MGNX
$207M
– –
-170,000
Closed -$3.48M –
OMER icon
46
Omeros
OMER
$1.36B
– –
-265,300
Closed -$2.63M –
KA icon
47
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,071
Closed -$1.84M –
AGRX
48
DELISTED
Agile Therapeutics
AGRX
– –
-8
Closed -$85K –
TRIL
49
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-110,000
Closed -$622K –
AKAO
50
DELISTED
Achaogen Inc
AKAO
– –
-80,000
Closed -$1.04M –
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2017 Portfolio in Review

As of Q1 2017, Opaleye Management held 53 positions worth $201M, up 18% from $170M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opaleye Management's Q1 2017 filing shows 12 new, 15 increased, 7 reduced and 9 closed positions. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 730,000 shares worth $7.84M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q1 2017 buy was Novelion Therapeutics Inc. Common Shares: 730,000 shares worth $7.84M.
  • Opaleye Management added most to Ocular Therapeutix in Q1 2017, an estimated $3.8M increase.
  • Opaleye Management's biggest Q1 2017 reduction was Neurogene, cutting an estimated $3.95M.
  • Opaleye Management fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $12.4M.
  • Opaleye Management's ten largest holdings make up 56% of its $201M portfolio in Q1 2017.
  • Opaleye Management opened 12 new positions and closed 9 in Q1 2017.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $201M.

Based on Opaleye Management's 13F filing for Q1 2017, filed 15 May 2017.